APBB3

Across TCGA pan-cancer cohorts, APBB3 Mutation is linked to patient survival in 8 of 34 cancer types, making it a survival-associated APBB3 data layer compared with 24 for mass-spec protein.

The strongest signal is observed in esophageal carcinoma (ESCA), where higher APBB3 Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated APBB3 expression acts as an unfavorable survival marker.

ESCA, LUSC, and THCA are the cancer types where APBB3 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
ESCA	DFS	Median	II,III,IV	0.082	0.523	<.001	12	view →
LUSC	OS	Median	II,III,IV	0.216	0.742	.013	12	view →
THCA	OS	Median	All	0.277	0.954	<.001	6	view →
BLCA	OS	Median	III,IV	0.232	0.686	.004	6	view →
PRAD	DFS	Median	All	0.085	0.774	<.001	6	view →
CHOL	OS	Median	All	0.155	0.725	.029	3	view →
ACC	DFS	Median	All	0.195	0.748	.003	3	view →
LIHC	OS	Median	II,III,IV	0.239	0.715	.035	3	view →

Pink = unfavorable, green = favorable. Showing the 8 strongest of 8 lineages.

APBB3–ESCA (DFS)

Open the ESCA breakdown →